Article: article from journal or magazin.
De la nécessité des études coût-efficacité en ostéoporose. [The necessity of cost-effectiveness analysis in osteoporosis]
Revue Médicale Suisse
English Abstract Journal Article --- Old month value: Jun 13
Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. Major changes have recently occurred in the treatment of osteoporosis. The development of a valid economic model (Markov) in the field of osteoporosis is discussed, as well as these limitations. Intervention, such hip protectors, calcium and vitamin D, bisphosphonates, hormonal replacement therapy, SERMs, strontium ranelate, analogue of parathyroid hormone are analysed in the light of cost-effectiveness analyses.
Aged Aged, 80 and over Bone Density Conservation Agents/economics/therapeutic use Calcium/economics/therapeutic use Cost-Benefit Analysis Decision Making Diphosphonates/economics/therapeutic use Female Fractures, Bone/economics/prevention & control Health Care Costs Hip Fractures/economics/prevention & control Hormone Replacement Therapy/economics Humans Male Markov Chains Middle Aged Models, Economic Organometallic Compounds/economics/therapeutic use Osteoporosis/drug therapy/*economics Parathyroid Hormone/analogs & derivatives/economics Quality of Life Selective Estrogen Receptor Modulators/economics/therapeutic use Thiophenes/economics/therapeutic use Vitamin D/economics/therapeutic use
Last modification date